Stage IIIA Colon Cancer AJCC v8
specificStage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)
38
Centers
31
Active Trials
—
Cancer Funding
Top Centers for Stage IIIA Colon Cancer AJCC v8(38)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | University of Illinois Cancer CenterChicago, IL High-Volume Research Center | 73.2 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 55.5 |
| 3 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 55.5 |
| 4 | UC San Diego Moores Cancer CenterLa Jolla, CA NCI Comprehensive Active Research Program | 55.5 |
| 5 | NCI Comprehensive Active Research Program | 55.5 |
| 6 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 55.5 |
| 7 | NCI Comprehensive Active Research Program | 55.5 |
| 8 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 55.5 |
| 9 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 55.5 |
| 10 | USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive Active Research Program | 55.5 |
| 11 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 55.5 |
| 12 | Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive Active Research Program | 55.5 |
| 13 | NCI Comprehensive Active Research Program | 55.5 |
| 14 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 55.5 |
| 15 | NCI Clinical Active Research Program | 55.5 |
| 16 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 55.5 |
| 17 | Cedars-Sinai CancerLos Angeles, CA Active Research Program | 55.5 |
| 18 | VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive Active Research Program | 55.5 |
| 19 | Georgetown Lombardi Comprehensive Cancer CenterWashington, DC NCI Comprehensive Active Research Program | 55.5 |
| 20 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 55.5 |
| 21 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 55.5 |
| 22 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive Active Research Program | 55.5 |
| 23 | University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical Active Research Program | 55.5 |
| 24 | Boston University Cancer CenterBoston, MA Active Research Program | 55.5 |
| 25 | Cancer Center at IllinoisUrbana, IL Active Research Program | 55.5 |
| 26 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 55.5 |
| 27 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL Active Research Program | 55.5 |
| 28 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program | 55.5 |
| 29 | University of Texas Medical Branch Cancer CenterGalveston, TX Active Research Program | 55.5 |
| 30 | Louisiana Cancer Research CenterNew Orleans, LA Active Research Program | 55.5 |
| 31 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive | 33.6 |
| 32 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive | 33.6 |
| 33 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive | 33.6 |
| 34 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive | 33.6 |
| 35 | NCI Comprehensive | 33.6 |
| 36 | NCI Comprehensive | 33.6 |
| 37 | Moffitt Cancer CenterTampa, FL NCI Comprehensive | 33.6 |
| 38 | Fox Chase Cancer CenterPhiladelphia, PA NCI Comprehensive | 33.6 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →